Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

To date, it remains challenging for clinicians to make informed decisions about which dosage of erenumab is more effective for treating adult patients with migraine. Thus, we sought to examine the safety and efficacy of different doses of erenumab in this group of patients.

Methods

We searched several databases from inception to May 31, 2021, irrespective of language. We included only RCTs that compared erenumab 70 mg, erenumab 140 mg, and placebo in migraine patients. The primary efficacy outcome was change in monthly migraine days (MMDs). The primary safety outcome was defined as treatment-emergent adverse events (TEAEs). We reported relative risks (RRs) with 95% credible intervals (CrIs) from the analysis.

Results

Overall, eight trials comprising 4281 participants were included in this study. Network meta-analysis showed that both erenumab 70 mg (MD: − 1.43, 95% CrI: − 1.71 to − 1.16) and erenumab 140 mg (MD: − 1.78, 95% CrI: − 2.21 to − 1.45) were associated with decreased MMDs. Also, erenumab 140 mg was associated with significantly lower MMDs than erenumab 70 mg (MD: − 0.34, 95% CrI: − 0.68 to − 0.01). In terms of primary safety outcome, neither erenumab 70 mg (RR: 0.98, 95% CrI: 0.92 to 1.05) nor erenumab 140 mg (RR: 0.99, 95% CrI: 0.91 to 1.07) was associated with increased risk of TEAEs.

Conclusions

The results from this study suggested erenumab 140 mg might provide better efficacy than 70 mg among adult patients with migraine, without increasing TEAEs. Future elaborated RCTs with a larger number of participants are warranted to validate these discoveries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Woldeamanuel YW, Cowan RP (2017) Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci 372:307–315. https://doi.org/10.1016/j.jns.2016.11.071

    Article  PubMed  Google Scholar 

  2. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB (2015) The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 35(7):563–578. https://doi.org/10.1177/0333102414552532

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K (2013) Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia 33(3):171–181. https://doi.org/10.1177/0333102412468668

    Article  CAS  PubMed  Google Scholar 

  4. American Headache Society (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59(1):1–18. https://doi.org/10.1111/head.13456

    Article  Google Scholar 

  5. Diener HC (2014) CGRP as a new target in prevention and treatment of migraine. Lancet Neurol 13(11):1065–1067. https://doi.org/10.1016/s1474-4422(14)70228-5

    Article  CAS  PubMed  Google Scholar 

  6. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6. https://doi.org/10.1186/s10194-018-0955-y

    Article  PubMed  PubMed Central  Google Scholar 

  7. Administration. FaD (accessed 1 July 2021) AIMOVIG (erenumabaooe). Highlights of prescribing information. Available at: https://www.accessdatafdagov/drugsatfda_docs/label/2020/761077s007lblpdf

  8. Agency. EM (accessed 1 July 2021) Human medicine European public assessment report (EPAR): Aimovig. Available at: https://www.emaeuropaeu/en/medicines/human/EPAR/aimovig

  9. Zhu C, Guan J, Xiao H, Luo W, Tong R (2019) Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore) 98(52):e18483. https://doi.org/10.1097/MD.0000000000018483

    Article  Google Scholar 

  10. Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M (2019) Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs 79(4):417–431. https://doi.org/10.1007/s40265-019-01069-1

    Article  CAS  PubMed  Google Scholar 

  11. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, da Silva P, Lima G, Cheng S, Mikol DD (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. https://doi.org/10.1111/ene.14715

    Article  PubMed  PubMed Central  Google Scholar 

  12. Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD (2020) One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology 95(5):e469–e479. https://doi.org/10.1212/WNL.0000000000010019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784. https://doi.org/10.7326/M14-2385

    Article  PubMed  Google Scholar 

  14. The International Headache Society (2018) Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211. https://doi.org/10.1177/0333102417738202

  15. Jes Olesen (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(1):9–160. https://doi.org/10.1111/j.1468-2982.2003.00824.x

  16. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

    Article  PubMed  PubMed Central  Google Scholar 

  17. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–94. https://doi.org/10.1016/j.jclinepi.2010.04.026

    Article  PubMed  Google Scholar 

  18. McGavock J, Chauhan BF, Rabbani R, Dias S, Klaprat N, Boissoneault S, Lys J, Wierzbowski AK, Sakib MN, Zarychanski R, Abou-Setta AM (2020) Layperson-led vs professional-led behavioral interventions for weight loss in pediatric obesity: a systematic review and meta-analysis. JAMA Netw Open 3(7):e2010364. https://doi.org/10.1001/jamanetworkopen.2020.10364

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kim DK, Kim JH, Lee JY, Ku NS, Lee HS, Park JY, Kim JW, Kim KJ, Cho KS (2020) Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials. Lancet Infect Dis. https://doi.org/10.1016/s1473-3099(20)30121-3

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wang SJ, Roxas AA, Jr., Saravia B, Kim BK, Chowdhury D, Riachi N, Tai MS, Tanprawate S, Ngoc TT, Jing ZY, Mikol DD, Pandhi S, Wen S, Mondal S, Tenenbaum N, Hours-Zesiger P (2021) Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia. https://doi.org/10.1177/03331024211024160

  21. Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD (2021) Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache. https://doi.org/10.1111/head.14138

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tepper SJ, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40(6):543–553. https://doi.org/10.1177/0333102420912726

    Article  PubMed  Google Scholar 

  23. Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD (2019) A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 59(10):1731–1742. https://doi.org/10.1111/head.13652

    Article  PubMed  PubMed Central  Google Scholar 

  24. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280–2287. https://doi.org/10.1016/s0140-6736(18)32534-0

    Article  CAS  PubMed  Google Scholar 

  25. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026–1037. https://doi.org/10.1177/0333102418759786

    Article  PubMed  Google Scholar 

  26. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434. https://doi.org/10.1016/s1474-4422(17)30083-2

    Article  CAS  PubMed  Google Scholar 

  27. Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132. https://doi.org/10.1056/NEJMoa1705848

    Article  CAS  PubMed  Google Scholar 

  28. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382–390. https://doi.org/10.1016/s1474-4422(16)00019-3

    Article  CAS  PubMed  Google Scholar 

  29. Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirguliyev S, Al-Karagholi MA, Amin FM, Sessa M (2021) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opin Drug Saf 20(4):467–474. https://doi.org/10.1080/14740338.2021.1866537

    Article  CAS  PubMed  Google Scholar 

  30. Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C (2016) Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356(1):223–231. https://doi.org/10.1124/jpet.115.227793

    Article  CAS  PubMed  Google Scholar 

  31. Andreou AP, Fuccaro M, Lambru G (2020) The role of erenumab in the treatment of migraine. Ther Adv Neurol Disord 13:1756286420927119. https://doi.org/10.1177/1756286420927119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https://doi.org/10.1186/s10194-020-01127-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the National key R&D Program of China (NO. 2018YFA0108604; NO. 2018YFA0108603) and the 1·3·5 project for disciplines of excellence—Clinical Research Incubation Project, West China Hospital, Sichuan University (2018HXFH010; 2018HXFH008).

Author information

Authors and Affiliations

  1. Department of Neurosurgery, West China Hospital, Sichuan University, St. Guoxuexiang, No. 37, Chengdu, Sichuan, 610041, People’s Republic of China

    Xing Wang, Qiang He, Dingke Wen, Lu Ma & Chao You

  2. West China Brain Research Centre, Sichuan University, Chengdu, Sichuan, 610041, People’s Republic of China

    Chao You

Authors
  1. Xing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiang He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dingke Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lu Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chao You
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CY and XW designed the meta-analysis, QH and XW searched for relevant studies, DW and XW selected the studies and extracted the relevant information, XW and LM synthesized the data, and XW wrote the first draft of the paper. All authors revised the manuscript and approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

Corresponding author

Correspondence to Chao You.

Ethics declarations

Ethical approval

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Xing Wang, Qiang He, and Dingke Wen contributed equally to this work as first authors

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 4135 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., He, Q., Wen, D. et al. Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons. Neurol Sci 43, 2751–2758 (2022). https://doi.org/10.1007/s10072-021-05701-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-021-05701-5

Keywords

Search

Navigation